{"product_id":"enlicitide-an-oral-pill-that-cuts-bad-cholesterol-by-more-than-half-what-a-major-clinical-trial-found","title":"Enlicitide: An Oral Pill That Cuts “Bad” Cholesterol by More Than Half — What a Major Clinical Trial Found","description":"\u003cp\u003eIn a large international clinical trial called CORALreef Lipids, researchers tested a new daily pill called enlicitide (en-li-SY-tide) in people with high cholesterol and heart disease risk. After 24 weeks of treatment, participants who took enlicitide saw their \"bad\" LDL cholesterol drop by an average of 57.1%, while those who took a placebo saw a slight increase of 3.0% — a highly significant difference reaching -55.8 percentage points after adjustment. The oral medication, which blocks a liver protein known as PCSK9, continued to show strong cholesterol-lowering effects through 52 weeks, with a safety profile that appeared similar to placebo. If approved, enlicitide could become the first oral PCSK9 inhibitor, offering a pill alternative to currently available injectable therapies.\u003c\/p\u003e\n\n\u003ch1\u003eEnlicitide: An Oral Pill That Cuts “Bad” Cholesterol by More Than Half — What a Major Clinical Trial Found\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Study Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#findings\"\u003eKey Findings: LDL Cholesterol Reduction at 24 Weeks\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#secondary\"\u003eAdditional Lipid Improvements at 24 and 52 Weeks\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#safety\"\u003eSafety and Tolerability\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn a phase 3 trial of 2,909 adults, enlicitide lowered LDL cholesterol by 57.1% at 24 weeks versus a 3.0% increase with placebo.\u003c\/li\u003e\n\u003cli\u003eEnlicitide is an investigational oral PCSK9 inhibitor, offering a potential daily-pill alternative to injectable PCSK9 drugs.\u003c\/li\u003e\n\u003cli\u003eMore than two-thirds of enlicitide-treated patients reached the strict LDL goal of under 55 mg\/dL plus a 50% reduction.\u003c\/li\u003e\n\u003cli\u003eThe drug also reduced non-HDL cholesterol, apolipoprotein B, and lipoprotein(a) by significant amounts at 24 weeks.\u003c\/li\u003e\n\u003cli\u003eAdverse events appeared similar to placebo over 52 weeks, but effects on heart attacks or strokes are not yet proven.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\u003cp\u003eFor decades, clinical trials have shown that lowering low-density lipoprotein (LDL) cholesterol — often called \"bad\" cholesterol — helps prevent heart attacks, strokes, and other cardiovascular events. Benefits are seen even in people who start with LDL levels well below 70 mg\/dL (1.8 mmol\/L). Because of this, modern clinical guidelines recommend that the highest-risk patients aim for LDL cholesterol levels of 55 mg\/dL (1.4 mmol\/L) or lower.\u003c\/p\u003e\n\u003cp\u003eYet despite these recommendations, \u003cstrong\u003emore than half of patients still do not reach their target LDL levels\u003c\/strong\u003e. Many are already taking statins, the first-line cholesterol-lowering drugs, but they may need additional help.\u003c\/p\u003e\n\u003cp\u003eThe most powerful non-statin therapies currently available work by inhibiting a liver protein called proprotein convertase subtilisin–kexin type 9, or \u003cstrong\u003ePCSK9\u003c\/strong\u003e. When PCSK9 is blocked, more LDL receptors remain on liver cells, allowing the liver to remove more LDL cholesterol from the blood.\u003c\/p\u003e\n\u003cp\u003eTwo forms of PCSK9 inhibitors already exist: injectable monoclonal antibodies and a small interfering RNA (a type of genetic medicine) that is also given by injection. Studies have shown these injectable drugs reduce cardiovascular events in high-risk patients. However, despite their proven benefit, PCSK9 inhibitors are \u003cstrong\u003einfrequently used in clinical practice\u003c\/strong\u003e. One major reason is that they must be injected.\u003c\/p\u003e\n\u003cp\u003eThis trial was designed to evaluate a new option: \u003cstrong\u003eenlicitide decanoate\u003c\/strong\u003e, an oral macrocyclic peptide that blocks PCSK9 from binding to LDL receptors. Previous phase 1 and phase 2 studies showed short-term LDL reductions, but longer-term data were needed. The CORALreef Lipids trial set out to provide those longer-term results.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Study Was Conducted\u003c\/h2\u003e\n\n\u003ch3\u003eTrial Design and Oversight\u003c\/h3\u003e\n\u003cp\u003eCORALreef Lipids was a \u003cstrong\u003ephase 3, multinational, double-blind, randomized, placebo-controlled trial\u003c\/strong\u003e. It was conducted at 168 sites in 14 countries. “Double-blind” means neither the patients nor the research team knew who was receiving the active drug and who was receiving the placebo — a design that prevents bias.\u003c\/p\u003e\n\u003cp\u003eThe trial was sponsored by MSD (Merck \u0026amp; Co.), based in Rahway, New Jersey. It was designed by the sponsor in collaboration with a scientific advisory committee, and an independent data and safety monitoring board provided oversight. The trial protocol was approved by an institutional review board or independent ethics committee at each participating site. All participants gave written informed consent.\u003c\/p\u003e\n\u003cp\u003eData were collected at participating sites and analyzed by representatives of the sponsor, who vouched for the accuracy and completeness of the data. Academic authors interpreted the data. The first author drafted the manuscript with editorial support from a medical writer employed by the sponsor.\u003c\/p\u003e\n\n\u003ch3\u003eTrial Population\u003c\/h3\u003e\n\u003cp\u003eTo participate, adults had to be at least 18 years old and meet one of these two sets of criteria:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEstablished disease group:\u003c\/strong\u003e A history of a major atherosclerotic cardiovascular disease event and an LDL cholesterol level of \u003cstrong\u003e55 mg\/dL or higher\u003c\/strong\u003e. Major events included acute coronary syndrome, coronary revascularization, heart attack (myocardial infarction), ischemic stroke, cerebrovascular arterial revascularization, and peripheral artery disease with a history of acute limb ischemia, revascularization, or major amputation (meaning amputation of all or part of an arm or leg, not just fingers or toes).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAt-risk group:\u003c\/strong\u003e Intermediate-to-high risk for a first atherosclerotic cardiovascular event and an LDL cholesterol level of \u003cstrong\u003e70 mg\/dL or higher\u003c\/strong\u003e. This risk was defined by any of the following: heterozygous familial hypercholesterolemia (an inherited form of very high cholesterol), diabetes mellitus, stable angina, a previous transient ischemic attack (mini-stroke), symptomatic peripheral artery disease, or age 40 or older with a predicted 10-year cardiovascular risk of at least 7.5% by the American Heart Association and American College of Cardiology Pooled Cohort Equation (or an equivalent calculator), or a coronary-artery calcium score of at least 100 Agatston units (a marker of plaque in the heart arteries).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eParticipants were required to be on a \u003cstrong\u003estable dose of appropriate lipid-lowering therapy\u003c\/strong\u003e for at least 30 days before screening, including at least a moderate- or high-intensity statin, unless they had a documented history of unacceptable side effects from statins.\u003c\/p\u003e\n\u003cp\u003ePeople were excluded if they were actively receiving or had recently received a PCSK9 inhibitor, had uncontrolled high blood pressure or diabetes, had active liver disease, or had a triglyceride level of 400 mg\/dL (4.52 mmol\/L) or higher at screening.\u003c\/p\u003e\n\n\u003ch3\u003eTrial Procedures\u003c\/h3\u003e\n\u003cp\u003eParticipants were randomly assigned in a \u003cstrong\u003e2:1 ratio\u003c\/strong\u003e to receive either enlicitide decanoate at a dose of 20 mg daily or a matching placebo daily for 52 weeks. The enlicitide formulation included an excipient (a non-active ingredient) called \u003cstrong\u003esodium caprate\u003c\/strong\u003e, which acts as a permeation enhancer to help the drug be absorbed in the digestive tract. The placebo did not contain sodium caprate.\u003c\/p\u003e\n\u003cp\u003eRandomization was stratified (balanced) according to three factors:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eRenal function (estimated glomerular filtration rate, or eGFR, of ≥60 vs. \u0026lt;60 mL\/min\/1.73 m²)\u003c\/li\u003e\n  \u003cli\u003eBaseline statin use\u003c\/li\u003e\n  \u003cli\u003eGeographic region\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eParticipants were told to take the pill in the morning on an empty stomach and to \u003cstrong\u003ewithhold food and beverages other than water for 30 minutes\u003c\/strong\u003e after taking it. Study visits occurred at baseline and at weeks 4, 8, 16, 24, 36, and 52. After the 52-week treatment period, participants completed an 8-week safety follow-up or could choose to enroll in a separate open-label extension study (ClinicalTrials.gov number NCT06492291).\u003c\/p\u003e\n\n\u003ch3\u003eEnd Points (Outcome Measures)\u003c\/h3\u003e\n\u003cp\u003eThe \u003cstrong\u003eprimary end point\u003c\/strong\u003e was the mean percent change in LDL cholesterol level from baseline to week 24. Key secondary end points were tested in a specific order:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eMean percent change in LDL cholesterol level from baseline to week 52\u003c\/li\u003e\n  \u003cli\u003eMean percent change in non–high-density lipoprotein (non-HDL) cholesterol level from baseline to week 24\u003c\/li\u003e\n  \u003cli\u003eMean percent change in apolipoprotein B level from baseline to week 24\u003c\/li\u003e\n  \u003cli\u003ePercent change in lipoprotein(a) — an inherited risk factor — from baseline to week 24\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eOther secondary end points included achieving an LDL cholesterol level of \u003cstrong\u003eless than 70 mg\/dL\u003c\/strong\u003e along with a 50% or greater reduction from baseline, and achieving an LDL level of \u003cstrong\u003eless than 55 mg\/dL\u003c\/strong\u003e along with a 50% or greater reduction.\u003c\/p\u003e\n\u003cp\u003eSafety end points included adverse events, discontinuation due to adverse events, and two prespecified topics of clinical interest: \u003cstrong\u003enew or worsening diabetes mellitus\u003c\/strong\u003e and \u003cstrong\u003edrug-induced liver injury\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eLaboratory Methods\u003c\/h3\u003e\n\u003cp\u003eThroughout the trial, LDL cholesterol levels were calculated using the Martin–Hopkins equation. At baseline, LDL cholesterol was also directly measured by beta quantification in all participants. During follow-up, beta quantification was used if the calculated LDL level was 40 mg\/dL (1.03 mmol\/L) or lower, if data were missing, or if triglycerides were 400 mg\/dL or higher. Central laboratories in five locations performed all measurements.\u003c\/p\u003e\n\n\u003ch3\u003eStatistical Analysis\u003c\/h3\u003e\n\u003cp\u003eThe planned sample size was 2,760 participants, designed to provide at least 1,500 participants exposed to enlicitide for about 52 weeks. The researchers estimated that, assuming a standard deviation of 25%, a true -50 percentage-point difference between groups in the mean percent change in LDL, and 5% discontinuation by week 24, the trial would have \u003cstrong\u003emore than 99% statistical power\u003c\/strong\u003e at a one-sided alpha of 0.025 for the primary end point.\u003c\/p\u003e\n\u003cp\u003eThe primary analysis used an analysis of covariance (ANCOVA) model with treatment, renal function, and geographic region as fixed effects and baseline LDL cholesterol as a covariate. Missing data (including data from participants who died) were handled with a “washout imputation” approach, in which missing values were imputed based on changes observed in the placebo group — a conservative method. A nonparametric bootstrap approach with 1,000 samples was used for statistical inference. For the lipoprotein(a) endpoint, a stratified Wilcoxon test was used, with multiple imputation for missing data.\u003c\/p\u003e\n\u003cp\u003eA post hoc reanalysis was also performed after database lock, because some baseline beta-quantification LDL values of 0 or less were determined to be biologically impossible. In that reanalysis, beta-quantification results with LDL values of 0 or less were set to missing, and Martin–Hopkins results were used when available.\u003c\/p\u003e\n\n\u003ch2 id=\"findings\"\u003eKey Findings: LDL Cholesterol Reduction at 24 Weeks\u003c\/h2\u003e\n\n\u003ch3\u003eParticipant Disposition and Baseline Characteristics\u003c\/h3\u003e\n\u003cp\u003eA total of \u003cstrong\u003e2,912 participants\u003c\/strong\u003e were randomly assigned between August 2023 and July 2025: 1,942 to enlicitide and 970 to placebo. Three participants were enrolled at multiple sites in separate enlicitide trials and were excluded, leaving \u003cstrong\u003e2,909 participants in the intention-to-treat population\u003c\/strong\u003e. Of these, 5 did not receive the assigned treatment, leaving \u003cstrong\u003e2,904 participants (1,935 on enlicitide and 969 on placebo)\u003c\/strong\u003e for efficacy and safety analyses.\u003c\/p\u003e\n\u003cp\u003eCompletion rates were high: \u003cstrong\u003e94.6%\u003c\/strong\u003e of the enlicitide group and \u003cstrong\u003e94.7%\u003c\/strong\u003e of the placebo group completed the trial, including 88.4% and 88.9% who continued treatment through the end of the 52-week period. Adherence was strong, with an \u003cstrong\u003eoverall mean adherence of 97.2%\u003c\/strong\u003e, and it was similar in both groups.\u003c\/p\u003e\n\u003cp\u003eThe two groups were well balanced. The mean age was \u003cstrong\u003e62.8 ± 10.7 years\u003c\/strong\u003e, and \u003cstrong\u003e39.3% of participants were women\u003c\/strong\u003e. The racial and ethnic breakdown was: 53.9% White, 27.6% Hispanic or Latino, and 26.3% Asian. More than half (58.3%) had a previous major atherosclerotic cardiovascular event.\u003c\/p\u003e\n\u003cp\u003eAt baseline, \u003cstrong\u003e96.6% of participants were taking a statin\u003c\/strong\u003e (95.4% on a moderate- or high-intensity statin), and \u003cstrong\u003e25.8% were taking ezetimibe or hybuthimibe\u003c\/strong\u003e (additional cholesterol-lowering drugs).\u003c\/p\u003e\n\n\u003ch3\u003ePrimary End Point: LDL Change at Week 24\u003c\/h3\u003e\n\u003cp\u003eAt baseline, the mean LDL cholesterol level was \u003cstrong\u003e95.0 ± 38.8 mg\/dL (2.46 ± 1.00 mmol\/L)\u003c\/strong\u003e in the enlicitide group and \u003cstrong\u003e98.3 ± 39.2 mg\/dL (2.54 ± 1.01 mmol\/L)\u003c\/strong\u003e in the placebo group.\u003c\/p\u003e\n\u003cp\u003eBy week 24, the mean LDL level had fallen to \u003cstrong\u003e38.7 ± 35.6 mg\/dL (1.00 ± 0.92 mmol\/L)\u003c\/strong\u003e in the enlicitide group, while the placebo group’s mean was essentially unchanged at \u003cstrong\u003e98.6 ± 42.5 mg\/dL (2.55 ± 1.10 mmol\/L)\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eIn the primary analysis, the mean percent change in LDL cholesterol from baseline to week 24 was:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e−57.1%\u003c\/strong\u003e (95% confidence interval [CI], −61.8 to −52.5) with enlicitide\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e+3.0%\u003c\/strong\u003e (95% CI, 0.9 to 5.1) with placebo\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAfter adjustment for baseline LDL cholesterol, renal function, and geographic region, the between-group difference was \u003cstrong\u003e−55.8 percentage points\u003c\/strong\u003e (95% CI, −60.9 to −50.7; P\u0026lt;0.001). In plain language, enlicitide lowered LDL by about 56 percentage points more than placebo, a result that is statistically overwhelming (a less than 0.1% probability of happening by chance). The benefit was consistent across subgroups (as shown in Figure S3 of the supplementary material).\u003c\/p\u003e\n\n\u003ch3\u003ePost Hoc Reanalysis\u003c\/h3\u003e\n\u003cp\u003eIn the post hoc reanalysis that corrected for biologically impossible baseline LDL values, the between-group difference in the mean percent change in LDL cholesterol was even larger: \u003cstrong\u003e−59.7 percentage points\u003c\/strong\u003e (95% CI, −62.3 to −57.1). This confirms that the main result was robust to different ways of handling unusual lab values.\u003c\/p\u003e\n\n\u003ch2 id=\"secondary\"\u003eAdditional Lipid Improvements at 24 and 52 Weeks\u003c\/h2\u003e\n\u003cp\u003eAll key secondary end points also favored enlicitide, and all differences were highly significant (P\u0026lt;0.001 for all comparisons).\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLDL cholesterol at week 52:\u003c\/strong\u003e The adjusted between-group difference was \u003cstrong\u003e−47.6 percentage points\u003c\/strong\u003e (95% CI, −52.7 to −42.5; P\u0026lt;0.001), showing that the large LDL reduction was maintained with long-term use.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNon-HDL cholesterol at week 24:\u003c\/strong\u003e The adjusted between-group difference was \u003cstrong\u003e−53.4 percentage points\u003c\/strong\u003e (95% CI, −55.5 to −51.2; P\u0026lt;0.001). Non-HDL reflects all the “bad” cholesterol in the blood, including LDL and other atherogenic particles.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eApolipoprotein B at week 24:\u003c\/strong\u003e The adjusted between-group difference was \u003cstrong\u003e−50.3 percentage points\u003c\/strong\u003e (95% CI, −52.1 to −48.5; P\u0026lt;0.001). Apolipoprotein B is a protein carried on all atherogenic particles and is a very strong predictor of heart disease risk.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLipoprotein(a) at week 24:\u003c\/strong\u003e The median between-group difference in the percent change was \u003cstrong\u003e−28.2 percentage points\u003c\/strong\u003e (95% CI, −30.3 to −26.0; P\u0026lt;0.001). Lipoprotein(a), or Lp(a), is an inherited, genetically determined risk factor for heart disease; reducing it is considered a potential additional benefit.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eAchieving Guideline-Based LDL Goals\u003c\/h3\u003e\n\u003cp\u003eThe study also measured how many patients reached the strict LDL targets recommended for high-risk individuals:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAn LDL level of less than 70 mg\/dL and a 50% or greater reduction from baseline:\u003c\/strong\u003e achieved by \u003cstrong\u003e70.3%\u003c\/strong\u003e of enlicitide-treated participants vs. \u003cstrong\u003e1.5%\u003c\/strong\u003e of placebo-treated participants.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAn LDL level of less than 55 mg\/dL and a 50% or greater reduction from baseline:\u003c\/strong\u003e achieved by \u003cstrong\u003e67.5%\u003c\/strong\u003e of enlicitide-treated participants vs. \u003cstrong\u003e1.2%\u003c\/strong\u003e of placebo-treated participants.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThese numbers demonstrate that enlicitide allowed the majority of patients to reach the very low LDL levels now recommended for people at the highest cardiovascular risk.\u003c\/p\u003e\n\u003cp\u003e(Changes in HDL, or “good,” cholesterol and triglycerides were reported in the supplementary materials but were not part of the hierarchical testing in this analysis.)\u003c\/p\u003e\n\n\u003ch2 id=\"safety\"\u003eSafety and Tolerability\u003c\/h2\u003e\n\u003cp\u003eThe researchers reported that the \u003cstrong\u003eincidence of adverse events did not appear to differ between the enlicitide and placebo groups\u003c\/strong\u003e. This is reassuring for a new medication, although the results are limited by the 52-week duration of the trial.\u003c\/p\u003e\n\u003cp\u003eAs is standard in such studies, the trial prespecified two safety topics of special interest: \u003cstrong\u003enew or worsening diabetes\u003c\/strong\u003e and \u003cstrong\u003edrug-induced liver injury\u003c\/strong\u003e. The main results section of the article notes that safety analyses included all participants who received at least one dose of study medication; no detailed numbers for these specific safety topics are reported in the abstract or main summary, but they will presumably appear in future detailed safety reports or the supplementary appendix.\u003c\/p\u003e\n\u003cp\u003eThe study also recorded discontinuations due to adverse events, and the completion rates above (88–89% continued to the end of the 52-week treatment period) suggest that the drug was generally well tolerated.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\u003cp\u003eThis is the first phase 3 trial to show that an \u003cstrong\u003eoral\u003c\/strong\u003e PCSK9 inhibitor can produce LDL reductions of the same magnitude as injectable PCSK9 drugs, which typically lower LDL by 50–60%. If enlicitide is approved by regulators, patients might soon have a pill option that is far less burdensome than injections.\u003c\/p\u003e\n\u003cp\u003eThe practical implications are significant:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConvenience:\u003c\/strong\u003e A daily pill can be taken at home without needles, potentially improving long-term adherence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGoal attainment:\u003c\/strong\u003e More than two-thirds of enlicitide-treated patients reached the very strict LDL goal of \u0026lt;55 mg\/dL with ≥50% reduction, a target that many patients today fail to achieve.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eComprehensive lipid benefits:\u003c\/strong\u003e Beyond LDL, enlicitide also reduced non-HDL cholesterol, apolipoprotein B, and Lp(a) — three additional markers that contribute to cardiovascular risk.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePotential for earlier use:\u003c\/strong\u003e An oral agent could be used alongside statins and ezetimibe without requiring patients to visit a clinic for injections. It may also be appropriate for people who are reluctant to start injectable therapy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe current evidence is mechanistic: it shows enlicitide improves lipid levels. What we do not yet know is whether these LDL reductions will translate into fewer heart attacks and strokes. However, given the long-established causal relationship between LDL lowering and cardiovascular event reduction — supported by dozens of trials over decades — it is reasonable to expect that a 57% reduction in LDL would significantly lower risk. The FDA and other regulatory authorities will review this evidence, and longer-term cardiovascular outcome trials will be important to confirm clinical benefits.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\u003cp\u003eNo single trial is perfect, and this one has several limitations that patients and clinicians should keep in mind:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSurrogate end point:\u003c\/strong\u003e The primary outcome was LDL cholesterol, not heart attacks, strokes, or deaths. LDL cholesterol is an established surrogate, but the actual reduction in cardiovascular events has not yet been measured in this drug’s development program.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDuration:\u003c\/strong\u003e Twelve months (52 weeks) is longer than early-phase studies but is still relatively short for a chronic medication. Long-term safety — especially regarding diabetes and liver effects — requires more observation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo active comparator:\u003c\/strong\u003e The trial compared enlicitide to placebo, not to injectable PCSK9 inhibitors. Head-to-head trials would be needed to know whether enlicitide performs as well as or better than the injectable options in direct comparison.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePopulation selection:\u003c\/strong\u003e The trial excluded people with uncontrolled hypertension or diabetes, active liver disease, and very high triglycerides. Results may not apply to those groups.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAdherence requirements:\u003c\/strong\u003e The drug must be taken on an empty stomach, with no food or beverages (other than water) for 30 minutes after the dose. This is manageable but could be challenging for some patients, and the 97% adherence seen in a clinical trial may not reflect real-world use.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eData-handling complexities:\u003c\/strong\u003e The trial used sophisticated statistical imputation methods and a post hoc reanalysis to handle unusual beta-quantification results. Although the reanalysis confirmed the primary result, such complexities highlight the need for careful interpretation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\u003cp\u003eIf you are at high risk for heart disease or have had a previous cardiovascular event, here’s what this study means for you and what you can do now:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your numbers.\u003c\/strong\u003e Ask your doctor about your LDL cholesterol, non-HDL cholesterol, apolipoprotein B, and lipoprotein(a) levels. The target LDL for high-risk patients is generally 55 mg\/dL or lower.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStay on your statin.\u003c\/strong\u003e Statins are the bedrock of cholesterol management. In this trial, 96.6% of participants were taking a statin, and enlicitide was tested on top of statin therapy. Never stop a statin without talking to your doctor.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRecognize the “injectable” barrier.\u003c\/strong\u003e If your doctor has suggested an injectable PCSK9 inhibitor and you are avoiding it because of needles, understand that injectable drugs are proven to reduce heart attacks and strokes. In the future, an oral option may become available, but don’t wait to address elevated LDL if it is currently above goal.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about add-on therapies.\u003c\/strong\u003e If you are still far from your LDL goal on a maximally tolerated statin, ask whether ezetimibe, an injectable PCSK9 inhibitor, or enrollment in clinical trials like the enlicitide program is appropriate for you.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWatch for study updates.\u003c\/strong\u003e Longer-term data and cardiovascular outcome trials are needed. If enlicitide is approved, follow the official prescribing information and discuss it with your healthcare provider.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAdopt a heart-healthy lifestyle.\u003c\/strong\u003e Medications are powerful, but they work best alongside a diet low in saturated fats, regular physical activity, weight management, smoking cessation, and control of blood pressure and diabetes.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is enlicitide and how does it work?\u003c\/h3\u003e\n\u003cp\u003eEnlicitide is an experimental daily oral pill that blocks a liver protein called PCSK9. Blocking PCSK9 leaves more LDL receptors on liver cells, allowing the liver to remove more 'bad' LDL cholesterol from the blood. It was tested as an add-on to statins in people with high cholesterol and heart disease risk.\u003c\/p\u003e\n\u003ch3\u003eWho was eligible for the CORALreef Lipids trial?\u003c\/h3\u003e\n\u003cp\u003eAdults with either a history of major cardiovascular events and LDL ≥55 mg\/dL, or intermediate-to-high risk for a first event and LDL ≥70 mg\/dL. They had to be on a stable statin dose unless statins caused unacceptable side effects. People with uncontrolled blood pressure, active liver disease, or very high triglycerides were excluded.\u003c\/p\u003e\n\u003ch3\u003eWill enlicitide reduce heart attacks or strokes?\u003c\/h3\u003e\n\u003cp\u003eNot yet known. The trial measured LDL cholesterol levels, not actual heart attacks or strokes. LDL cholesterol is an established surrogate, and the expectation is that a large LDL reduction would lower risk, but longer-term cardiovascular outcome trials are still needed to confirm clinical benefits.\u003c\/p\u003e\n\u003ch3\u003eWhat side effects were seen with enlicitide?\u003c\/h3\u003e\n\u003cp\u003eThe incidence of adverse events appeared similar between enlicitide and placebo over 52 weeks. The trial specifically monitored new or worsening diabetes and drug-induced liver injury, though detailed numbers were not in the main summary. About 88–89% of participants continued treatment through the full year.\u003c\/p\u003e\n\u003ch3\u003eWho should not take enlicitide?\u003c\/h3\u003e\n\u003cp\u003eThe trial excluded people with uncontrolled high blood pressure or diabetes, active liver disease, or triglycerides of 400 mg\/dL or higher. Results may not apply to these groups. Always talk to your doctor about whether any new medication is safe for your specific health situation.\u003c\/p\u003e\n\u003ch3\u003eMy LDL is still high on a statin. Should I get a second opinion about trying the new oral PCSK9 inhibitor enlicitide instead of an injectable PCSK9 inhibitor?\u003c\/h3\u003e\n\u003cp\u003eA second opinion is reasonable if your LDL remains above goal despite a maximally tolerated statin and you are weighing an injectable PCSK9 inhibitor, ezetimibe, or waiting for enlicitide. In the large clinical trial, enlicitide lowered LDL by about 57% compared with placebo, and most patients reached strict LDL targets. However, that trial measured cholesterol levels, not heart attacks or strokes, and lasted only 52 weeks. An independent expert can help you decide whether these results apply to your heart risk and current treatment. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Ann Marie Navar, M.D., Ph.D., Elina Mikhailova, M.D., Ph.D., Alberico L. Catapano, Ph.D., Puja Banka, M.D., Dirk J. Blom, M.D., Alberto Cadena, M.D., Susan Kourpanidis, M.S., Norman E. Lepor, M.D., Kazuhisa Tsukamoto, M.D., Ph.D., Geraldine Mendizabal, M.D., Julio Nunez, M.D., Wenjuan Zhang, Ph.D., Pengfei Zhu, D.Phil., Min Zhuo, M.D., M.P.H., and Christie M. Ballantyne, M.D., for the CORALreef Lipids Investigators\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e The New England Journal of Medicine\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication details:\u003c\/strong\u003e February 5, 2026, Vol. 394, No. 6, pages 529–539. DOI: 10.1056\/NEJMoa2511002. ClinicalTrials.gov number: NCT05952856.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c\/strong\u003e MSD (Rahway, NJ).\u003c\/p\u003e\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research published in The New England Journal of Medicine. It is intended for educational purposes and does not provide individual medical advice. Always consult a qualified healthcare professional for medical decisions.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47527612317852,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/fr\/products\/enlicitide-an-oral-pill-that-cuts-bad-cholesterol-by-more-than-half-what-a-major-clinical-trial-found","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}